Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MP0250 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MP0250 | EXPERIMENTAL | see section "intervention description" below |
| Name | Type | Description |
|---|---|---|
| MP0250 | DRUG | Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions. |
Inclusion Criteria: 1. Male or female ≥ 18 years 2. Histologically confirmed and documented advanced or metastatic solid tumour refractory to at least 1 prior regimen of standard treatment or for which no curative therapy is available and for whom MP0250 is a reasonable option 3. Progressive or sta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
MP0250 is an investigational small molecule being studied for the treatment of cancer, including multiple myeloma in relapse. It is currently in clinical development and has not been approved by regulatory authorities.
MP0250 is being developed by Molecular Partners AG, a biopharmaceutical company traded on the NASDAQ under the ticker symbol MOLN.
MP0250 is in Phase 1 of clinical development. It is an investigational drug and has not yet received regulatory approval for any indication.
MP0250 has been studied in two clinical trials. The first, NCT02194426, was a first-in-human study in cancer patients. The second, NCT03136653, was a Phase 2 trial of MP0250 plus bortezomib and dexamethasone in patients with multiple myeloma in relapse.
MP0250 is the sole name used for this investigational drug in the clinical trial records. No alternative names have been associated with it in the available data.